Evidence map›Paper›PMID 31409360›Full record

ArticleMalaria journal2019

Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL-α tag.

Emily M Stucke, Amadou Niangaly, Andrea A Berry, Jason A Bailey, Drissa Coulibaly, Amed Ouattara, Kirsten E Lyke, Matthew B Laurens, Antoine Dara, Matthew Adams and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Malaria: past, present, and future.Signal transduction and targeted therapy · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 3 countries.

Emily M StuckeMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Amadou NiangalyMalaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali.
Andrea A BerryMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Jason A BaileyThe EMMES Corporation, Rockville, MD, USA.
Drissa CoulibalyMalaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali.
Amed OuattaraMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Kirsten E LykeMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Matthew B LaurensMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Antoine DaraMalaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali.
Matthew AdamsMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Jozelyn PabloDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, CA, USA.
Algis JasinskasDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, CA, USA.
Rie NakajimaDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, CA, USA.
Albert E ZhouMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Sonia AgrawalMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
DeAnna J Friedman-KlabanoffMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Shannon Takala-HarrisonMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Bourema KouribaMalaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali.
Abdoulaye K KoneMalaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali.
J Alexandra RoweCentre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.
Ogobara K DoumboMalaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali.
Philip L FelgnerDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, CA, USA.
Mahamadou A TheraMalaria Research and Training Center, University of Science, Techniques and Technologies of Bamako, Bamako, Mali.
Christopher V PloweDuke Global Health Institute, Duke University, Durham, NC, USA.
Mark A TravassosMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. mtravass@som.umaryland.edu.ORCID http://orcid.org/0000-0002-6045-3322
University of Maryland, Baltimore · USUniversité des Sciences, des Techniques et des Technologies de Bamako · MLUniversity of California, Irvine · USCentre for Immunity, Infection and Evolution · GBDuke University · USEmmes (United States) · US

Funding

EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Safety, Immunogenicity and Efficacy of VaccineU19AI065683 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2005 to 2009
$4.7M
Safety and efficacy of PfSPZ malaria vaccine in malaria-exposed adultsU01AI112367 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LAURENS, MATTHEW BRENT · 2015 to 2018
$2.8M
Variant surface antigens in cerebral malaria pathogenesisR01HL130750 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI FISHER, STEVEN A., HARRISON, SHANNON TAKALA · 2015 to 2018
$2.1M
Protein microarray antibody responses to P. falciparum in a human challenge modelK23AI125720 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2017 to 2021
$915k
Designing a diversity-covering multiantigen multi-strain vaccineK01HL140285 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI OUATTARA, AMED · 2019 to 2023
$712k
Host vulnerability and parasite genetics in the development of cerebral malariaR01AI099628 · NIAID · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI THERA, MAHAMADOU ALI · 2014 to 2018
$625k
The role of RIFINs and their interaction with blood type in vulnerability to severe malaria in Malian childrenF30HL146095 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI ZHOU, ALBERT E · 2019 to 2021
$126k
Identification of parasite erythrocyte membrane antigens specific to cerebral malaria and severe malarial anemia pathogenesisF31HL147471 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI STUCKE, EMILY MARIE · 2019 to 2021
$83k
National Institute of Allergy and Infectious Diseases R01AI099628National Institute of Allergy and Infectious Diseases U01AI112367National Institute of Allergy and Infectious Diseases U19AI065683NHLBI NIH HHS F30 HL146095NHLBI NIH HHS F31 HL147471NHLBI NIH HHS K01 HL140285NHLBI NIH HHS R01 HL130750NIAID NIH HHS K23 AI125720NIAID NIH HHS R01 AI099628NIGMS NIH HHS 2 R25-GM55036NIGMS NIH HHS R25 GM055036
6 · The paper itself

Abstract

backgroundPlasmodium falciparum erythrocyte membrane protein-1 (PfEMP1) antigens play a critical role in host immune evasion. Serologic responses to these antigens have been associated with protection from clinical malaria, suggesting that antibodies to PfEMP1 antigens may contribute to natural immunity. The first N-terminal constitutive domain in a PfEMP1 is the Duffy binding-like alpha (DBL-α) domain, which contains a 300 to 400 base pair region unique to each particular protein (the DBL-α "tag"). This DBL-α tag has been used as a marker of PfEMP1 diversity and serologic responses in malaria-exposed populations. In this study, using sera from a malaria-endemic region, responses to DBL-α tags were compared to responses to the corresponding entire DBL-α domain (or "parent" domain) coupled with the succeeding cysteine-rich interdomain region (CIDR).

methodsA protein microarray populated with DBL-α tags, the parent DBL-CIDR head structures, and downstream PfEMP1 protein fragments was probed with sera from Malian children (aged 1 to 6 years) and adults from the control arms of apical membrane antigen 1 (AMA1) vaccine clinical trials before and during a malaria transmission season. Serological responses to the DBL-α tag and the DBL-CIDR head structure were measured and compared in children and adults, and throughout the season.

resultsMalian serologic responses to a PfEMP1's DBL-α tag region did not correlate with seasonal malaria exposure, or with responses to the parent DBL-CIDR head structure in either children or adults. Parent DBL-CIDR head structures were better indicators of malaria exposure.

conclusionsLarger PfEMP1 domains may be better indicators of malaria exposure than short, variable PfEMP1 fragments such as DBL-α tags. PfEMP1 head structures that include conserved sequences appear particularly well suited for study as serologic predictors of malaria exposure.

Indexed as

AdultAntigens, ProtozoanChildChild, PreschoolConserved SequenceHumansInfantMalaria, FalciparumMiddle AgedPlasmodium falciparumProtein Structure, TertiaryProtozoan ProteinsYoung AdultAntigens, Protozoanerythrocyte membrane protein 1, Plasmodium falciparumProtozoan ProteinsImmunityMalariaMicroarrayPfEMP1Plasmodium falciparumSeroreactivityvar genes

Identifiers

PMID31409360
PMCPMC6692945
OpenAlexW2967358023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.